FREE SHIPPING ON ORDERS OVER $150

glp 1 agonist addiction IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 medications are getting attention

$24.35

Quantity
- +
Description

Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains

glp 1 agonist addiction IUPHAR review Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 medications are getting attention

Wireko, A.A

glp 1 agonist addiction IUPHAR review Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 medications are getting attention

Mechanism of Action Incretins hormones like GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are released throughout the day, increasing at mealtimes

glp 1 agonist addiction IUPHAR review Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 medications are getting attention

Watanabe Y, Saisho Y, Inaishi J, et al

glp 1 agonist addiction IUPHAR review Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 medications are getting attention

Recently, the MET-097i candidate was originally developed for once-weekly administration, but its extended half-life also qualifies it for once-monthly dosing [62]

glp 1 agonist addiction IUPHAR review Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 medications are getting attention

2024, doi: 10.1111/dom.15869

glp 1 agonist addiction IUPHAR review Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 medications are getting attention

You may also like

Frontiers

US$ 29.31

4.2 (11 reviews)

Frontiers

US$ 22.90

4.5 (6 reviews)

recommand products